A Non-interventional Registry for Patients With Hepatitis B Virus Infection
Condition(s) studied
Investigational drug(s) / intervention(s)
No intervention: No intervention
Study summary
In order to tackle the unmet needs in chronic HBV infection, a consortium of clinical partners has gathered to establish a registry for patients with hepatitis B mono- and co-infections. The partners will build up a European-wide registry to be able to stratify patients for upcoming clinical trials.
Extensive analyses of virus and host-specific parameters are to be carried out from these patients. The knowledge gained thereby should contribute to a better understanding of the HBV control and enable patient stratification with regard to immunomodulatory therapies.
Furthermore, hepatitis B patients are to be identified who are willing to participate in future studies to investigate immunotherapies to cure HBV infections (e.g. therapeutic vaccines).
Eligibility
Primary outcome measure(s)
- Number of patients with change HBsAg levels — 5 years
Regular assessment of quantitative HBsAg levels - Number of patients with seroconversion to anti-HBs — 5 years
Measurement of quantitative HBsAg and anti-HBs levels - Quantification of IL6, IP-10, IFNg and IL1beta and correlation with HBsAg and ALT levels — 5 years
Cytokine and Chemokine quantification in patients for subsequent correlation with viral parameters
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Hannover Medical School | Hanover | Germany | Recruiting |
More Hannover Medical School trials in Germany
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05051098 on ClinicalTrials.gov ↗ ← All trials in Germany